667 related articles for article (PubMed ID: 28058024)
1. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
[TBL] [Abstract][Full Text] [Related]
2. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
O'Connell J; Rowan C; Stack R; Harkin G; Parihar V; Chan G; Breslin N; Cullen G; Dunne C; Egan L; Harewood G; Leyden J; MacCarthy F; MacMathuna P; Mahmud N; McKiernan S; McNamara D; Mulcahy H; Murray F; O'Connor A; O'Toole A; Patchett S; Ryan B; Sheridan J; Slattery E; Doherty G; Kevans D
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1019-1026. PubMed ID: 29878945
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
4. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
5. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
Tursi A; Allegretta L; Buccianti N; Della Valle N; Elisei W; Forti G; Faggiani R; Gallina S; Hadad Y; Larussa T; Lauria A; Luzza F; Lorenzetti R; Mocci G; Penna A; Polimeni N; Pranzo G; Ricciardelli C; Zampaletta C; Picchio M
J Gastrointestin Liver Dis; 2017 Sep; 26(3):239-244. PubMed ID: 28922435
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
9. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
Taxonera C; Rodríguez C; Bertoletti F; Menchén L; Arribas J; Sierra M; Arias L; Martínez-Montiel P; Juan A; Iglesias E; Algaba A; Manceñido N; Rivero M; Barreiro-de Acosta M; López-Serrano P; Argüelles-Arias F; Gutierrez A; Busquets D; Gisbert JP; Olivares D; Calvo M; Alba C;
Inflamm Bowel Dis; 2017 Aug; 23(8):1394-1402. PubMed ID: 28671873
[TBL] [Abstract][Full Text] [Related]
11. Golimumab for moderate to severe ulcerative colitis.
Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
[TBL] [Abstract][Full Text] [Related]
12. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
[TBL] [Abstract][Full Text] [Related]
16. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
Bossuyt P; Baert F; D'Heygere F; Nakad A; Reenaers C; Fontaine F; Franchimont D; Dewit O; Van Hootegem P; Vanden Branden S; Lambrecht G; Ferrante M;
Inflamm Bowel Dis; 2019 Jan; 25(1):156-162. PubMed ID: 29920582
[TBL] [Abstract][Full Text] [Related]
17. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
[TBL] [Abstract][Full Text] [Related]
19. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
De Vos M; Dewit O; D'Haens G; Baert F; Fontaine F; Vermeire S; Franchimont D; Moreels T; Staessen D; Terriere L; Vander Cruyssen B; Louis E;
J Crohns Colitis; 2012 Jun; 6(5):557-62. PubMed ID: 22398050
[TBL] [Abstract][Full Text] [Related]
20. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
Telesco SE; Brodmerkel C; Zhang H; Kim LL; Johanns J; Mazumder A; Li K; Baribaud F; Curran M; Strauss R; Paxson B; Plevy S; Davison T; Knight L; Dibben S; Schreiber S; Sandborn W; Rutgeerts P; Siegel CA; Reinisch W; Greenbaum LE
Gastroenterology; 2018 Oct; 155(4):1008-1011.e8. PubMed ID: 29981298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]